NKGEN BIOTECH INC (NKGN) Stock News

NASDAQ:NKGN - US65488A1016 - Common Stock

0.1913 USD

-0.32 (-62.91%)

Last: 3/4/2025, 8:00:02 PM

0.19 USD

0 (-0.68%)

After Hours: 3/4/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NKGN Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: NKGen Biotech, Inc.

NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer’s Trial with Activation of Clinical Sites in Canada and Florida

4 months ago - By: NKGen Biotech, Inc.

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations

4 months ago - By: NKGen Biotech, Inc.

NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

5 months ago - By: NKGen Biotech, Inc.

NKGen Biotech To Present on the Use of Troculeucel for Alzheimer’s and Parkinson’s Disease at the 7th China International Biotechnology Conference & Exhibition

5 months ago - By: NKGen Biotech, Inc.

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)

6 months ago - By: NKGen Biotech, Inc.

NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)

6 months ago - By: NKGen Biotech, Inc.

NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit

6 months ago - By: NKGen Biotech

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

6 months ago - By: NKGen Biotech

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

6 months ago - By: NKGen Biotech

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

6 months ago - By: NKGen Biotech

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

7 months ago - By: NKGen Biotech

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

7 months ago - By: NKGen Biotech

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

7 months ago - By: NKGen Biotech

NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site

7 months ago - By: NKGen Biotech

NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site

7 months ago - By: Benzinga - Mentions: MBRX PRPH HCTI MTNB ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

7 months ago - By: NKGen Biotech

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease

7 months ago - By: Benzinga - Mentions: AWH PRPH RDHL AVGR ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

7 months ago - By: NKGen Biotech

NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease

9 months ago - By: NKGen Biotech, Inc.

NKGen Biotech Selected as Stalking Horse Bidder for NKMax

9 months ago - By: NKGen Biotech, Inc.

NKGen Biotech Selected as Stalking Horse Bidder for NKMax

9 months ago - By: NKGen Biotech, Inc.

NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel

9 months ago - By: NKGen Biotech, Inc.

NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel

10 months ago - By: NKGen Biotech

NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference